Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.
about
Innate immune sensing of DNA virusesDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsThe role of chromatin in adenoviral vector functionAdenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantationA new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic targetPre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutininAdenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentDevelopment of adenoviral vector-based mucosal vaccine against influenza.Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyGeneration of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation.Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors.Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.Viral capsid is a pathogen-associated molecular pattern in adenovirus keratitisAdenoviral vector immunity: its implications and circumvention strategies.Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology.Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.Direct evidence from single-cell analysis that human {alpha}-defensins block adenovirus uncoating to neutralize infection.TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.Innate immune recognition of viruses and viral vectors.MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus.beta-Arrestins modulate Adenovirus-vector-induced innate immune responses: differential regulation by beta-arrestin-1 and beta-arrestin-2.The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells.Unabated adenovirus replication following activation of the cGAS/STING-dependent antiviral response in human cells.Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.Gene therapy for rhesus monkeys heterozygous for LDL receptor deficiency by balloon catheter hepatic delivery of helper-dependent adenoviral vector.Helper-dependent adenoviral vectors for liver-directed gene therapy.The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.Implications of the innate immune response to adenovirus and adenoviral vectors.NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo.Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.Virus infection recognition and early innate responses to non-enveloped viral vectors.The role of endosomal escape and mitogen-activated protein kinases in adenoviral activation of the innate immune response.T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigationTimely synthesis of the adenovirus type 5 E1B 55-kilodalton protein is required for efficient genome replication in normal human cells.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic AdenovirusToll-like receptor 9 inhibition reduces mortality in polymicrobial sepsisDifferential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.
P2860
Q24626598-C9661724-953A-4578-8D80-A61E62F8D57CQ26782083-22E20AD2-70C9-48CB-A9E4-C9CA9E30CFFCQ26995655-6CAF4405-12BA-4531-8698-D803B329C514Q27004695-C197183B-5F57-4052-94AB-6D757904E68BQ27324639-B8D37578-CC58-4816-869A-942810A1D9D7Q27333475-B0F2D96F-1953-4066-9B20-830A65F13309Q28731982-06FDA573-28D0-4E6B-9E8B-C258151FAD36Q28744136-1E625D72-11C0-4B6E-9524-83360D1FBEF8Q30396642-E9D296AA-1847-45F5-A7A5-DD8D2E52CEA3Q30899557-B9203F9A-06C8-4179-BFD2-F76D56FF2232Q30980638-899A01CE-B26D-4A82-8122-3E66ED7D17C9Q33380283-71E16045-E888-4006-97B0-AB57546C1836Q33382953-43FFB06D-0F27-4F59-BB2F-3809439E71A0Q33564368-BA479699-EA49-4EAA-B089-AA5D7062A5B7Q33565630-A0240349-3483-44D0-9A35-387C5278CA26Q33591243-B0BF8E89-D5BE-413B-8ABE-54D31D429379Q33747762-5F14A90C-1AC6-49F3-974D-2B51823AA483Q33769294-91BF91A3-E77C-4EDE-81EC-DCE47CCA9782Q33785096-072FCF21-A7A3-4FC2-842A-FFA460B93A24Q33805229-62DF164C-F7C0-4AF6-A867-C85B1399B57EQ33832157-E3EBAEA1-58A2-4F1C-8DB4-FEE8D7FA86CFQ33915868-703B8A05-060F-4252-92BE-90739857521AQ34388476-D13E23F3-81F3-451E-BDA8-EAA0B92F9A52Q34594959-7679A6D1-D4B8-4898-9199-F33E737BEF2AQ34717992-02BAF171-9150-45E4-96B3-D311E4AB172BQ34892789-6DCB69E0-7572-4E47-9408-77A37B99A47CQ34982825-8A3E4C94-1786-454A-8AFB-E3E2CFC0EEECQ35067592-EAA9E163-E1F4-4F56-BB9D-799F4DB71813Q35085363-928B9E09-A114-4D7B-B7B2-9F977909A1CBQ35226121-E0A64E9B-39A8-46D2-99B8-BBDBB65E1F06Q35238258-D5C90F8A-D9DB-40BC-9B16-BD383AA71784Q35260293-37D7A7B6-59F1-4B32-A2D0-5932B9F2199EQ35462794-5C882382-363C-44D6-B75D-E8FBCC6F0EEEQ35594838-8B8279E2-FC12-4EBC-B17A-BEF373DB26C7Q35695799-F2949923-47C9-44A5-B1FB-9ED6EA013B01Q35826320-65F1DDA4-43C2-4008-B541-628B527F5BD1Q36220624-9799EB19-21F2-4F44-AD59-EF53D4B4A1BCQ36582785-7A44D6F6-951B-4F67-9BC1-E5A56CF3B30AQ36699738-C5E659CC-3D5F-4D2E-9DA1-50541F60E5D3Q36740271-FBF8F9DC-83F7-4149-9152-F1FF42479CE3
P2860
Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Toll-like receptor 9 triggers ...... -dependent adenoviral vectors.
@en
Toll-like receptor 9 triggers ...... -dependent adenoviral vectors.
@nl
type
label
Toll-like receptor 9 triggers ...... -dependent adenoviral vectors.
@en
Toll-like receptor 9 triggers ...... -dependent adenoviral vectors.
@nl
prefLabel
Toll-like receptor 9 triggers ...... -dependent adenoviral vectors.
@en
Toll-like receptor 9 triggers ...... -dependent adenoviral vectors.
@nl
P2093
P356
P1433
P1476
Toll-like receptor 9 triggers ...... r-dependent adenoviral vectors
@en
P2093
Brendan Lee
Christian Clarke
John R Rodgers
Michael P Seiler
Terry K Bertin
Viraj Mane
P304
P356
10.1038/SJ.MT.6300031
P577
2007-02-01T00:00:00Z